In short
- The underarms have better evidence than any other site.
- A 2017 review of 50 studies, 32 of them randomised, found moderate-quality evidence of a large effect of botulinum toxin on underarm sweating compared with placebo.
- In the 322-person trial, the median duration at 50 units was 205 days, a little under seven months.
- See a doctor if the sweating is prolonged, excessive and unexplained; comes mostly at night; began at age 25 or later; or comes with weight loss, fever, a pounding heartbeat or shortness of breath.
- The first job is to make sure the sweating is not a sign of something else.
What is hyperhidrosis, and is it just sweating a lot?
Sweating is normal. People sweat in heat, when they exercise and when they are nervous, which is why the definition matters. Hyperhidrosis is sweating beyond what those triggers explain: sweating when it is cool or at rest, or that soaks through clothes with little cause. The main kind is primary focal hyperhidrosis. It affects the underarms, palms, soles or the face and scalp, usually on both sides equally, with no underlying cause found, and it often runs in families. About nine in ten people with hyperhidrosis have this primary kind, according to a 2019 dermatology review.
A United States survey of 8,160 people put the prevalence at 4.8%, and only half of those affected had ever raised it with a health professional, mostly because they thought it was not a medical condition or that nothing could be done. No Malaysian figure was found. It is not a trivial problem: among dermatology outpatients in Vancouver and Shanghai, anxiety affected 21% and depression 27% of people with hyperhidrosis, against 8% and 10% of those without.
How does botulinum toxin reduce sweating?
Sweat glands are switched on by nerve endings that release a chemical messenger, acetylcholine. Botulinum toxin injected into the skin blocks that release. The US label describes the result as temporary chemical denervation of the sweat gland, with a local reduction in sweating. For the underarms, the sweaty area is often mapped first with an iodine-starch test, which turns blue-black where there is sweat, and many small injections are then placed into the skin about 1 to 2 cm apart. The dose is counted in units, and units are not interchangeable between brands: the Botox insert gives 50 units per underarm and the Dysport insert 100. The clinic's page on anti-wrinkle injections covers how it uses botulinum toxin.
How well does it work, and for how long?
The underarms have better evidence than any other site. A 2017 review of 50 studies, 32 of them randomised, found moderate-quality evidence of a large effect of botulinum toxin on underarm sweating compared with placebo. In one 320-person trial, 94% of the treated group had cut sweat production by half or more at four weeks, against 36% on placebo, and 82% against 21% at 16 weeks; the US label gives 91% against 36% at four weeks for the same trial. In a 322-person, 52-week trial, the US label reports 81% of those given 50 units per underarm reaching that mark at four weeks, against 41% on placebo. Placebo groups improve too, so some response to saline is expected.
The effect is temporary. In the 322-person trial, the median duration at 50 units was 205 days, a little under seven months. The Botox insert gives an average of 6 to 10 months after a first treatment, with 27.5% of people going a year or longer, and the Dysport insert says about 48 weeks for most people. It is a repeating treatment. The inserts advise repeating only when the effect has faded, and not more often than every two months (Botox) or every 12 weeks (Dysport). How long anti-wrinkle injections last explains why the timing varies between people.
What about the palms?
Palm injections work too, but the evidence is smaller, the procedure is more painful, and the labels list underarm sweating as the licensed use, so treating the palms goes beyond what the label covers. A 2026 review of 19 studies found relief lasting 3 to 12 months, averaging 4.9 to 9.5 months for botulinum toxin type A. Injection into the palm is described as frequently accompanied by considerable pain, and a 19-person trial found that a cooling spray with a lidocaine cream gave less pain than the spray alone. Hand muscle weakness is the recognised cost: the US label warns that weakness of hand muscles may occur, and palm studies report it in 23% to 60% of people, usually mild and temporary, with rare cases of impaired grip. One 19-person trial found grip strength unchanged at 28 days. For the face, the label warns that eyelid droop may occur.
What are the side effects?
Underarm treatment is usually well tolerated. Injection-site pain is very common, with bleeding or bruising at the injection sites, headache and flu-like symptoms in some people. Sweating in other areas can increase: the Botox insert reports it in 4.5% of people within a month, resolving in about 30% of them within four months, and the Dysport insert lists compensatory sweating as common. In the 320-person trial, adverse events were reported by 11% of the treated group and 5% of the placebo group, a difference that was not statistically significant. Botox side effects: the common, the rare, and what to do covers the wider list.
The US label carries a boxed warning that the effect of botulinum toxin can spread beyond the injection site, causing generalised weakness, drooping eyelid, and swallowing or breathing difficulty hours to weeks after injection, with reports of death. The label's warnings section adds that no definitive serious reports of this spread have been made for severe underarm sweating at the recommended dose (100 units in all). It should not be used by anyone with an infection at the injection site or an allergy to the product, and the Malaysian Botox insert advises against use in pregnancy unless the benefit clearly outweighs the risk. Botulinum toxin is a prescription-only medicine in Malaysia, a Group B poison under the Poisons Act 1952 that a registered medical practitioner may supply, or a pharmacist may dispense on a doctor's prescription, and the Dysport insert says it should be given only by appropriately trained physicians.
What else helps?
Guidelines put simpler steps first. In the 2019 dermatology review, antiperspirants are first-line treatment for primary focal hyperhidrosis. Products with 10% to 20% aluminium chloride hexahydrate are the first line for underarm sweating, some are prescribed for nightly use, and they can irritate the skin. Deodorants reduce odour and do not stop sweat. A Canadian expert guideline puts topical aluminium chloride first for mild underarm, palm and sole sweating, and botulinum toxin and aluminium chloride both first-line when the sweating is severe, scoring 3 or 4 on a four-point scale of interference with daily activities.
Iontophoresis, a weak electric current passed through water, is the main option for palms and soles. It takes 10 to 30 minutes over several sessions, and rarely causes skin cracking or blisters. The 2017 review found weak but consistent evidence for it in the palms. Prescription anticholinergic medicines also reduce sweating: topical ones for the underarms beat placebo in a 2026 meta-analysis of eight randomised trials of 1,921 people, with more side effects such as dry mouth, and tablets are kept for sweating that is generalised or has resisted other treatment, at the cost of the same kind of side effects. Which products are registered in Malaysia is a question for a doctor or pharmacist.
Beyond that, devices that damage the sweat glands (microwave energy, lasers), local surgery to remove underarm sweat glands and, as a last resort, cutting the nerves that carry the sweating signal from the chest exist. The last of these can cause compensatory sweating elsewhere. The 2017 review rated the evidence for its other treatments, which included anticholinergic medicines, curettage and the energy devices, as low or very low quality, and did not review nerve surgery.
When does sweating need a medical check for another cause?
Primary hyperhidrosis is a diagnosis reached after other causes are considered. Sweating that comes from another condition, called secondary hyperhidrosis, tends to be more generalised or asymmetric than the primary kind. Features that point to a secondary cause include sweating that is one-sided or all over the body, that begins at age 25 or later, that comes with night sweats, or that has no family history. Causes include an overactive thyroid, low blood sugar, menopause, infections including tuberculosis, anxiety, some medicines, some cancers and adrenal gland tumours. Sweating together with chest pain can be a symptom of a heart attack, which needs emergency treatment in hospital.
See a doctor if the sweating is prolonged, excessive and unexplained; comes mostly at night; began at age 25 or later; or comes with weight loss, fever, a pounding heartbeat or shortness of breath. The NHS lists these reasons to see a GP about excessive sweating: self-help is not working, it has lasted at least six months, it stops you getting on with daily activities, it happens at least once a week or at night, it runs in the family, or you take medicine for another condition. The Botox insert itself says patients should be evaluated for causes of secondary hyperhidrosis, such as an overactive thyroid or an adrenal tumour, so that sweating is not treated as a symptom while its cause is missed. Skin specialist or aesthetic doctor explains which door to try first, and how to check an aesthetic doctor in Malaysia covers the registers.
Injections for sweating at this clinic
This clinic offers injections for excessive sweating. Botulinum toxin is a prescription-only medicine in Malaysia, so a doctor assesses you first, and whether to treat is decided after that assessment. Whether the same injections help the smell of sweat, as opposed to the wetness, is a separate question, answered in does botulinum toxin help body odour.
A drier underarm is a reasonable goal. The first job is to make sure the sweating is not a sign of something else.
Common questions
Does Botox stop underarm sweating?
It reduces it, and for most people it reduces it a great deal for months. In two randomised trials of about 320 people each, 81% to 94% of people given 50 units per underarm had cut their sweat production by half or more at four weeks, against 36% to 41% given placebo. It does not cure the condition, and the sweating returns when the effect wears off.
How long does Botox for sweating last?
The Botox insert gives an average of 6 to 10 months after a first treatment at 50 units per underarm, with 27.5% of people going a year or longer, and one trial found a median of 205 days. The Dysport insert says about 48 weeks for most people. For the palms, a 2026 review found botulinum toxin type A relief averaging 4.9 to 9.5 months. Treatment is repeated when the effect fades.
What are the side effects of Botox for sweating?
Injection-site pain is very common, with bleeding or bruising, headache and flu-like symptoms in some people. Sweating elsewhere increased in 4.5% of people in the Botox insert within a month. In the palms, temporary hand weakness is reported in a substantial share of people, and injection into the face can cause eyelid droop. The US label warns that the toxin's effect can spread beyond the injection site. It is a prescription-only medicine in Malaysia.
When should excessive sweating be checked by a doctor?
When it is prolonged and unexplained, comes mostly at night, began at age 25 or later, or comes with weight loss, fever, a pounding heartbeat or shortness of breath. Sweating together with chest pain can be a heart attack and needs emergency treatment. Sweating from another condition, such as an overactive thyroid, needs that condition found first, and the Botox insert says so.
Sources
- Naumann M, Lowe NJ. Botulinum toxin type A in treatment of bilateral primary axillary hyperhidrosis: randomised, parallel group, double blind, placebo controlled trial. BMJ 2001 320 people, 50 units per underarm: 94% against 36% responded at 4 weeks, 82% against 21% at 16 weeks; adverse events 11% against 5%, not significant.
- Lowe NJ et al. Botulinum toxin type A in the treatment of primary axillary hyperhidrosis: a 52-week multicenter double-blind, randomized, placebo-controlled study. J Am Acad Dermatol 2007 322 people: median duration 205 days at 50 units; 75% against 25% improved by two points on the four-point severity scale at 4 weeks (the sweat-production figure of 81% against 41% used in the article is from the US label's account of this trial).
- BOTOX (onabotulinumtoxinA) prescribing information, Allergan, revised August 2026, DailyMed Indication for severe underarm sweating, trial figures (81% against 41% and 91% against 36% at 4 weeks), mechanism, hand weakness with palm treatment, eyelid droop with facial treatment, boxed warning on spread of toxin effect, and the statement that no definitive serious reports of distant spread have been made for severe underarm sweating at the recommended 100 units.
- BOTOX package insert, Malaysia, NPRA Quest3+ register, MAL19970915ARZ (annotated proposed insert, May 2025) Registered underarm indication, 50 units per underarm, average effect 6 to 10 months, sweating elsewhere 4.5%, evaluation for secondary hyperhidrosis.
- Dysport package insert, Malaysia, NPRA Quest3+ register, MAL20000731AZ Axillary hyperhidrosis as an indication, 100 units per underarm, about 48 weeks, compensatory sweating common, only by trained physicians.
- Wade R et al. Interventions for hyperhidrosis in secondary care: a systematic review and value-of-information analysis. Health Technol Assess 2017 50 studies: moderate-quality evidence of a large effect of botulinum toxin for the underarms, weak but consistent evidence for iontophoresis in the palms, low or very low quality for the other interventions assessed (anticholinergic medicines, curettage, energy devices); nerve surgery was not reviewed.
- Nawrocki S, Cha J. The etiology, diagnosis, and management of hyperhidrosis: a comprehensive review, parts 1 and 2. J Am Acad Dermatol 2019 Definition, about 93% primary, secondary sweating more generalised and asymmetric, the treatment sequence, oral agents for generalised or resistant sweating, and compensatory sweating as a cost of sympathectomy.
- Solish N et al. A comprehensive approach to the recognition, diagnosis, and severity-based treatment of focal hyperhidrosis: recommendations of the Canadian Hyperhidrosis Advisory Committee. Dermatol Surg 2007 Aluminium chloride first for mild sweating, toxin and aluminium chloride both first-line for severe sweating.
- Hyperhidrosis, MedlinePlus Medical Encyclopedia, US National Library of Medicine, reviewed 3 June 2025 Primary and secondary hyperhidrosis, causes of secondary sweating, when to contact a provider, antiperspirant strength, iontophoresis and other treatments.
- Excessive sweating (hyperhidrosis), NHS When to see a doctor, and the options a specialist may suggest.
- Doolittle J et al. Hyperhidrosis: an update on prevalence and severity in the United States. Arch Dermatol Res 2016 4.8% prevalence in a survey of 8,160 people; about half had never discussed it with a professional.
- Bahar R et al. The prevalence of anxiety and depression in patients with or without hyperhidrosis. J Am Acad Dermatol 2016 Vancouver and Shanghai dermatology outpatients: anxiety 21% and depression 27% with hyperhidrosis, 8% and 10% without.
- Eze C et al. Sustained efficacy of botulinum toxin in primary palmar hyperhidrosis: a systematic review of duration, quality of life, and satisfaction. Front Med 2026 Palms: 3 to 12 months of effect, muscle weakness 23% to 60%, rare grip impairment, more limited evidence than for the underarms.
- Lowe NJ et al. Efficacy and safety of botulinum toxin type A in the treatment of palmar hyperhidrosis. Dermatol Surg 2002; Marani A et al. Pain control during treatment of primary palmar hyperhidrosis with botulinum toxin A. Toxins 2024 19 people, grip strength unchanged at 28 days; and a 19-person trial in which a cooling spray with liposomal lidocaine cream gave less pain than the spray alone for palm injections (PMID 38251244).
- Kim J et al. Efficacy and safety of topical anticholinergics in the treatment of primary axillary hyperhidrosis: a systematic review and meta-analysis. Clin Drug Investig 2026 Eight randomised trials, 1,921 people, topical glycopyrronium, sofpironium and umeclidinium: better than placebo, more side effects such as dry mouth.
- Poisons Act 1952 (Act 366), section 21, and the Poisons List updated per P.U.(A) 306/2023, Pharmaceutical Services Programme, Ministry of Health Malaysia Botulinum toxin is a Group B poison: supplied by a registered medical practitioner, or by a pharmacist on a doctor's prescription.
- Maazi M, Leung AK, Lam JM. Primary hyperhidrosis: an updated review. Drugs Context 2025 Secondary hyperhidrosis tends to be more generalised; features that point to it include one-sided or generalised sweating, onset at 25 or later, night sweats and no family history.
- Heart attack, NHS A heart attack needs emergency treatment in hospital; its symptoms include chest pain and sweating.
Disclosure: In 2022 Dr Ong was a key opinion leader for Botox for Allergan, which makes Botox, the Juvéderm range and CoolSculpting, and he has spoken for Allergan on botulinum toxin and at the CoolSculpting launch in Manila (2019). How he thinks about ties like these: The quiet we kept: what shapes what your doctor recommends.



